Biological pacing by gene and cell therapy

Netherlands Heart Journal

Volumn 15, Issue 9, 2007, Pages 318-322

  Boink, G J J ^a,b   Seppen, J ^a   De Bakker, J M T ^a,b   Tan, H L ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac arrhythmia therapy; Cell therapy; Gene therapy; Pacemakers

Indexed keywords

ADENYLATE CYCLASE; CALCIUM CHANNEL L TYPE; CYCLIC AMP; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; ION CHANNEL; UNCLASSIFIED DRUG;

ATRIOVENTRICULAR BLOCK; CELL THERAPY; DEPOLARIZATION; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; GENE THERAPY; HEART ARRHYTHMIA; HEART MUSCLE CELL; HYPERPOLARIZATION; MEMBRANE STEADY POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PROTEIN EXPRESSION; REVIEW; SICK SINUS SYNDROME; SINUS NODE;

EID: 35948973951     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086008     Document Type: Review

References (31)

1. Verkerk AO, Wilders R, van Borren MM, Peters RJ, Broekhuis E, Lam K, et al. Pacemaker current (If) in the human sinoatrial node. Eur Heart J. In press 2007.
2. Mistrik P, Mader R, Michalakis S, Weidinger M, Pfeifer A, Biel M. The murine HCN3 gene encodes a hyperpolarization-activated cation channel with slow kinetics and unique response to cyclic nucleotides. J Biol Chem 2005;280:27056-61.
3. Seifert R, Scholten A, Gauss R, Mincheva A, Lichter P, Kaupp UB. Molecular characterization of a slowly gating human hyperpolarization-activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci USA 1999;96:9391-6.
4. Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999;85:e1-e6.
5. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005;21:1115-22.
6. Rosen MR, Brink PR, Cohen IS, Robinson RB. Genes, stem cells and biological pacemakers. Cardiovasc Res 2004;64:12-23.
7. Miake J, Marbán E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest 2003;111:1529-36.
8. Miake J, Marbán E, Nuss HB. Biological pacemaker created by gene transfer. Nature 2002;419:132-3.
9. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995;122:701-14.
10. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, et al. R. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002;110: 381-8.
11. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005;111:2720-6.
12. Qu J, Barbuti A, Protas L, Santoro B, Cohen IS, Robinson RB. HCN2 overexpression in newborn and adult ventricular myocytes: distinct effects on gating and excitability. Circ Res 2001;89:E8-14.
13. Qu J, Plotnikov AN, Danilo P Jr, Shlapakova I, Cohen IS, Robinson RB, et al. Expression and function of a biological pacemaker in canine heart. Circulation 2003;107:1106-9.
14. Bucchi A, Plotnikov AN, Shlapakova I, Danilo P Jr., Kryukova Y, Qu J, et al. Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation 2006;114:992-9.
15. Tse HF, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 2006;114:1000-11.
16. Borer JS. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med 2004;1:103-9.
17. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005;21:1115-22.
18. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282-6.
19. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22:1282-9.
20. Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 2005;111:11-20.
21. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature 2006;441:1097-9.
22. Rosen MR. 15th annual Gordon K. Moe Lecture. Biological pacemaking: in our lifetime? Heart Rhythm 2005;2:418-28.
23. Potapova I, Plotnikov A, Lu Z, Danilo P Jr, Valiunas V, Qu J, et al. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res 2004;94:952-9.
24. Robinson RB, Rosen MR, Brink PR, Cohen IS. Letter regarding the article by Xue et al, "Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes". Circulation 2005;112:e82-e83.
25. Fleury S, Simeoni E, Zuppinger C, Déglon N, von Segesser LK, Kappenberger L, et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 2003;107:2375-82.
26. Seppen J, Barry SC, Harder B, Osborne WRA. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 2001;98:594-6.
27. Seppen J, van Til NP, van der Rijt R, Hiralall JK, Kunne C, Oude Elferink RPJ. Immune response to lentiviral bilirubin UDP-glucuronosyltransferase gene transfer in fetal and neonatal rats. Gene Ther 2006;13:672-7.
28. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99:e3-e9.
29. Rosen AB, Kelly DJ, Schuldt AJ, Lu J, Potapova IA, Doronin SV, et al. Finding Fluorescent Needles in the Cardiac Haystack: Tracking Human Mesenchymal Stem Cells Labeled with Quantum Dots for Quantitative In Vivo 3-D Fluorescence Analysis. Stem Cells 2007 May 10 (Epub ahead of print).
30. Boink GJJ, Verkerk AO, van Amersfoorth SC, Tasseron S, van der Meulen J, de Bakker JMT, et al. Increased spontaneous activity and autonomic modulation in lentiviral transduced rat cardiac myocytes overexpressing HCN4. Heart Rhythm 2007 (meeting abstract).
31. Biel M, Schneider A, Wahl C. Cardiac HCN channels: structure, function, and modulation. Trends Cardiovasc Med 2002;12:206-12.